VTVT
vTv Therapeutics Inc.
Set alert
- YTD
- -37.06%
- 1 year
- +19.46%
- Open
- 25.85
- Prev close
- 26.38
- Mkt cap
- 99.52M
- Vol
- 14.22K
- Avg vol
- 49.36K
- EPS
- -0.72
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 24.69
- High
- 26.31
- Forward P/E
- -42.03
- Beta
- 0.63
- Short ratio
- 1.50
- Inst. own
- 14.95%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 15.00
- 200-d avg
- 18.63
- 1y target
- 35.00
Key statistics
- Market cap
- 36.23M
- Enterprise value
- -7.53M
- Trailing P/E
- 0.00
- Forward P/E
- -42.03
- PEG ratio
- 0.00
- Price / sales
- 36.23
- Price / book
- 0.00
- EPS (TTM)
- -4.37
- Beta
- 0.63
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.00M
- Revenue growth
- 0.00%
- Free cash flow
- -13.89M
- Total cash
- 45.59M
- Total debt
- 256.00K
- Return on equity
- -362.13%
- Shares outstanding
- 2.61M
- Short % of float
- 3.33%
- 50-day average
- 15.00
- 200-day average
- 18.63
Analyst view
Consensus: strong buy
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.87.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | 0.00 | -0.88 | — | — |
| Aug 8, 2024 | Jun 1, 2024 | 0.00 | -0.81 | — | — |
| May 9, 2024 | Mar 1, 2024 | 0.00 | -1.17 | — | — |
| Mar 13, 2024 | Dec 1, 2023 | 0.00 | -1.67 | — | — |
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | -3.20 | — | — |
| Aug 11, 2023 | Jun 1, 2023 | 0.00 | -2.80 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 9, 2024 | Alliance Global Partners | init | — | Buy |
About vTv Therapeutics Inc.
vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Group LLC.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- vtvtherapeutics.com
News
- vTv Therapeutics Announces First Patient Randomized In Phase 2a Hybrid CATT1 Study Of Cadisegliatin In Type 1 Diabetes
- vTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery Systems
- vTv Therapeutics Receives FDA's Orphan Drug Designation For HPPD To Treat Sickle Cell Disease
- vTv Therapeutics Completes Enrollment In Its Phase 3 Cadisegliatin As Adjunctive Therapy In Type 1 Diabetes Trial
Your note
Sign in to keep a note on VTVT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AKKARAJU SRINIVAS | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Feb 26, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Samsara BioCapital, LLC | 7.92% | 206,784 | 2.87M | Sep 29, 2024 |
| FMR, LLC | 6.82% | 178,200 | 2.47M | Sep 29, 2024 |
| Baker Bros. Advisors, LP | 3.73% | 97,314 | 1.35M | Sep 29, 2024 |
| Vanguard Group Inc | 1.59% | 41,558 | 576.41K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.39% | 10,307 | 142.96K | Sep 29, 2024 |
| Blackrock Inc. | 0.18% | 4,750 | 65.88K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Select Portfolios - Biotechnology | 6.82% | 178,200 | 2.47M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 1.29% | 33,666 | 466.95K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.29% | 7,654 | 106.16K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.20% | 5,198 | 72.10K | Oct 30, 2024 |
| Northern Small Cap Core Fund | 0.19% | 4,900 | 67.96K | Sep 29, 2024 |
| iShares Micro Cap ETF | 0.13% | 3,338 | 46.30K | Oct 30, 2024 |